Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Label Revisions Ordered for GLP-1 Agents to Add New Side Effect Risks
February 15, 2023
- Japan Should Create Drug Discovery Command Tower: Chugai Honorary Chair
February 14, 2023
- Trade Group Calls for Predictability around SaMD Reimbursement: LDP Gathering
February 14, 2023
- J-TEC’s Cell Sheet for Vitiligo Now in Line for Approval in Japan
February 14, 2023
- Japan Extends Paxlovid Shelf Life to 24 Months
February 13, 2023
- Japan Ends Supply of Moderna’s Original COVID Vaccine
February 13, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
- Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
- Pharma Trade Groups Stress Concern for Re-Pricing Debate over Xocova: Chuikyo
February 9, 2023
- Japan Panel OKs Next COVID Vaccine Rollout This Autumn, Winter
February 9, 2023
- Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- MHLW Council’s Efforts to Address Drug Lag Led to 371 Approvals to Date: Minister
February 8, 2023
- Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
- SCARDA to Beef Up Efforts to Discover Technologies Outside Infectious Diseases: AMED President
February 3, 2023
- MHLW Scratching Head over High-Price Drug Issue, Lecanemab in Mind: Bureau Chief
February 2, 2023
- Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica Now in Line for Approval
February 2, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…